Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
No information is available regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study evaluated the reduced risk of HCC in patients undergoing BSV treatment. A total of 188 patient...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-02, Vol.16 (5), p.887 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 887 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Yim, Hyung Joon Kang, Seong Hee Jung, Young Kul Ahn, Sang Hoon Kim, Won Yang, Jin Mo Jang, Jae Young Kweon, Yong Oh Cho, Yong Kyun Kim, Yoon Jun Hong, Gun Young Kim, Dong Joon Sohn, Joo Hyun Lee, Jin Woo Park, Sung Jae Yim, Sun Young Park, Jin Kyung Um, Soon Ho |
| description | No information is available regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study evaluated the reduced risk of HCC in patients undergoing BSV treatment. A total of 188 patients with CHB were treated with BSV for up to 8 years. We prospectively assessed the incidence of HCC compared with the risk from prediction models. During the follow-up, 5 patients developed HCC: 1 of 139 patients with non-cirrhotic CHB, and 4 of 49 patients with liver cirrhosis. We compared the HCC incidence in non-cirrhotic and cirrhotic patients with the predicted number derived from the REACH-B (risk estimation for HCC in CHB) model and GAG-HCC (guide with age, gender, HBV DNA, core promotor mutation, and cirrhosis) model, respectively. The standardized incidence ratio (SIR) was 0.128 (
= 0.039) at 7 years in non-cirrhotic CHB patients, and the SIR was 0.371 (
= 0.047) at 7.5 years in cirrhotic patients, suggesting a significantly decreased HCC incidence in both groups. HCC prediction was available for BSV-treated patients using existing models. In conclusion, BSV decreased the risk of HCC in patients with CHB, and prediction models were applicable. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806. |
| doi_str_mv | 10.3390/cancers16050887 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A786432137</galeid><sourcerecordid>A786432137</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-4072ebe458084eb9df0439998e3000d134900beb953d946f69e00952d9a93e193</originalsourceid><addsrcrecordid>eNptUsFuGyEUXFWtmijNubcKqZdeNoGFZeFUJVbbRLLUynLPCLNv7Zfuggu7jvL3xXJiJVHhAOLNDG-epig-MnrBuaaXznoHMTFJa6pU86Y4rWhTlVJq8fbZ_aQ4T-mO5sU5a2TzvjjhSjS8Euq0SAtoJwctWWD6Q0JHbmBrx-Cg76feRjKz0aEPgyXoyS87IvgxkXscN2S2icGjOzBwxESuyQIc4A79msyDX5dLiAO5hoRd2GEkyw1Eu334ULzrbJ_g_PE8K35__7ac3ZTznz9uZ1fz0gmlx1JkA7ACUSuqBKx021HBtdYKePbSMi40patcqHmrheykBkp1XbXaag5M87Pi60F3O60GaF1uPdrebCMONj6YYNG8rHjcmHXYGUY1p5qxrPDlUSGGvxOk0QyY9rOxHsKUTKVrKRVTmmbo51fQuzBFn_3tUbVgjc7tH1Fr24NB34X8sduLmqtGScErxpuMuvgPKu8WBnTBQ4f5_QXh8kBwMaQUoTuaZNTss2JeZSUzPj2fzRH_lAz-Dy3Zuf4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955417904</pqid></control><display><type>article</type><title>Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy</title><source>PubMed Central Open Access</source><source>PubMed (Medline)</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB Electronic Journals Library</source><creator>Yim, Hyung Joon ; Kang, Seong Hee ; Jung, Young Kul ; Ahn, Sang Hoon ; Kim, Won ; Yang, Jin Mo ; Jang, Jae Young ; Kweon, Yong Oh ; Cho, Yong Kyun ; Kim, Yoon Jun ; Hong, Gun Young ; Kim, Dong Joon ; Sohn, Joo Hyun ; Lee, Jin Woo ; Park, Sung Jae ; Yim, Sun Young ; Park, Jin Kyung ; Um, Soon Ho</creator><creatorcontrib>Yim, Hyung Joon ; Kang, Seong Hee ; Jung, Young Kul ; Ahn, Sang Hoon ; Kim, Won ; Yang, Jin Mo ; Jang, Jae Young ; Kweon, Yong Oh ; Cho, Yong Kyun ; Kim, Yoon Jun ; Hong, Gun Young ; Kim, Dong Joon ; Sohn, Joo Hyun ; Lee, Jin Woo ; Park, Sung Jae ; Yim, Sun Young ; Park, Jin Kyung ; Um, Soon Ho</creatorcontrib><description>No information is available regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study evaluated the reduced risk of HCC in patients undergoing BSV treatment. A total of 188 patients with CHB were treated with BSV for up to 8 years. We prospectively assessed the incidence of HCC compared with the risk from prediction models. During the follow-up, 5 patients developed HCC: 1 of 139 patients with non-cirrhotic CHB, and 4 of 49 patients with liver cirrhosis. We compared the HCC incidence in non-cirrhotic and cirrhotic patients with the predicted number derived from the REACH-B (risk estimation for HCC in CHB) model and GAG-HCC (guide with age, gender, HBV DNA, core promotor mutation, and cirrhosis) model, respectively. The standardized incidence ratio (SIR) was 0.128 (
= 0.039) at 7 years in non-cirrhotic CHB patients, and the SIR was 0.371 (
= 0.047) at 7.5 years in cirrhotic patients, suggesting a significantly decreased HCC incidence in both groups. HCC prediction was available for BSV-treated patients using existing models. In conclusion, BSV decreased the risk of HCC in patients with CHB, and prediction models were applicable. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16050887</identifier><identifier>PMID: 38473248</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Antigens ; Care and treatment ; Cirrhosis ; Clinical trials ; Comparative analysis ; Gender ; Hepatitis B ; Hepatocellular carcinoma ; Hepatoma ; Infections ; Liver ; Liver cancer ; Liver cirrhosis ; Medical research ; Medicine, Experimental ; Mutation ; Nucleotide analogs ; Patients ; Prediction models ; Risk factors ; Surveillance ; Ultrasonic imaging</subject><ispartof>Cancers, 2024-02, Vol.16 (5), p.887</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 by the authors. 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-4072ebe458084eb9df0439998e3000d134900beb953d946f69e00952d9a93e193</citedby><cites>FETCH-LOGICAL-c489t-4072ebe458084eb9df0439998e3000d134900beb953d946f69e00952d9a93e193</cites><orcidid>0000-0002-5792-1500 ; 0000-0002-2926-1007 ; 0000-0001-9141-7773 ; 0000-0002-8977-4509</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930911/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930911/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38473248$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yim, Hyung Joon</creatorcontrib><creatorcontrib>Kang, Seong Hee</creatorcontrib><creatorcontrib>Jung, Young Kul</creatorcontrib><creatorcontrib>Ahn, Sang Hoon</creatorcontrib><creatorcontrib>Kim, Won</creatorcontrib><creatorcontrib>Yang, Jin Mo</creatorcontrib><creatorcontrib>Jang, Jae Young</creatorcontrib><creatorcontrib>Kweon, Yong Oh</creatorcontrib><creatorcontrib>Cho, Yong Kyun</creatorcontrib><creatorcontrib>Kim, Yoon Jun</creatorcontrib><creatorcontrib>Hong, Gun Young</creatorcontrib><creatorcontrib>Kim, Dong Joon</creatorcontrib><creatorcontrib>Sohn, Joo Hyun</creatorcontrib><creatorcontrib>Lee, Jin Woo</creatorcontrib><creatorcontrib>Park, Sung Jae</creatorcontrib><creatorcontrib>Yim, Sun Young</creatorcontrib><creatorcontrib>Park, Jin Kyung</creatorcontrib><creatorcontrib>Um, Soon Ho</creatorcontrib><title>Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>No information is available regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study evaluated the reduced risk of HCC in patients undergoing BSV treatment. A total of 188 patients with CHB were treated with BSV for up to 8 years. We prospectively assessed the incidence of HCC compared with the risk from prediction models. During the follow-up, 5 patients developed HCC: 1 of 139 patients with non-cirrhotic CHB, and 4 of 49 patients with liver cirrhosis. We compared the HCC incidence in non-cirrhotic and cirrhotic patients with the predicted number derived from the REACH-B (risk estimation for HCC in CHB) model and GAG-HCC (guide with age, gender, HBV DNA, core promotor mutation, and cirrhosis) model, respectively. The standardized incidence ratio (SIR) was 0.128 (
= 0.039) at 7 years in non-cirrhotic CHB patients, and the SIR was 0.371 (
= 0.047) at 7.5 years in cirrhotic patients, suggesting a significantly decreased HCC incidence in both groups. HCC prediction was available for BSV-treated patients using existing models. In conclusion, BSV decreased the risk of HCC in patients with CHB, and prediction models were applicable. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806.</description><subject>Age</subject><subject>Antigens</subject><subject>Care and treatment</subject><subject>Cirrhosis</subject><subject>Clinical trials</subject><subject>Comparative analysis</subject><subject>Gender</subject><subject>Hepatitis B</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Infections</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Mutation</subject><subject>Nucleotide analogs</subject><subject>Patients</subject><subject>Prediction models</subject><subject>Risk factors</subject><subject>Surveillance</subject><subject>Ultrasonic imaging</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptUsFuGyEUXFWtmijNubcKqZdeNoGFZeFUJVbbRLLUynLPCLNv7Zfuggu7jvL3xXJiJVHhAOLNDG-epig-MnrBuaaXznoHMTFJa6pU86Y4rWhTlVJq8fbZ_aQ4T-mO5sU5a2TzvjjhSjS8Euq0SAtoJwctWWD6Q0JHbmBrx-Cg76feRjKz0aEPgyXoyS87IvgxkXscN2S2icGjOzBwxESuyQIc4A79msyDX5dLiAO5hoRd2GEkyw1Eu334ULzrbJ_g_PE8K35__7ac3ZTznz9uZ1fz0gmlx1JkA7ACUSuqBKx021HBtdYKePbSMi40patcqHmrheykBkp1XbXaag5M87Pi60F3O60GaF1uPdrebCMONj6YYNG8rHjcmHXYGUY1p5qxrPDlUSGGvxOk0QyY9rOxHsKUTKVrKRVTmmbo51fQuzBFn_3tUbVgjc7tH1Fr24NB34X8sduLmqtGScErxpuMuvgPKu8WBnTBQ4f5_QXh8kBwMaQUoTuaZNTss2JeZSUzPj2fzRH_lAz-Dy3Zuf4</recordid><startdate>20240222</startdate><enddate>20240222</enddate><creator>Yim, Hyung Joon</creator><creator>Kang, Seong Hee</creator><creator>Jung, Young Kul</creator><creator>Ahn, Sang Hoon</creator><creator>Kim, Won</creator><creator>Yang, Jin Mo</creator><creator>Jang, Jae Young</creator><creator>Kweon, Yong Oh</creator><creator>Cho, Yong Kyun</creator><creator>Kim, Yoon Jun</creator><creator>Hong, Gun Young</creator><creator>Kim, Dong Joon</creator><creator>Sohn, Joo Hyun</creator><creator>Lee, Jin Woo</creator><creator>Park, Sung Jae</creator><creator>Yim, Sun Young</creator><creator>Park, Jin Kyung</creator><creator>Um, Soon Ho</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5792-1500</orcidid><orcidid>https://orcid.org/0000-0002-2926-1007</orcidid><orcidid>https://orcid.org/0000-0001-9141-7773</orcidid><orcidid>https://orcid.org/0000-0002-8977-4509</orcidid></search><sort><creationdate>20240222</creationdate><title>Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy</title><author>Yim, Hyung Joon ; Kang, Seong Hee ; Jung, Young Kul ; Ahn, Sang Hoon ; Kim, Won ; Yang, Jin Mo ; Jang, Jae Young ; Kweon, Yong Oh ; Cho, Yong Kyun ; Kim, Yoon Jun ; Hong, Gun Young ; Kim, Dong Joon ; Sohn, Joo Hyun ; Lee, Jin Woo ; Park, Sung Jae ; Yim, Sun Young ; Park, Jin Kyung ; Um, Soon Ho</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-4072ebe458084eb9df0439998e3000d134900beb953d946f69e00952d9a93e193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Antigens</topic><topic>Care and treatment</topic><topic>Cirrhosis</topic><topic>Clinical trials</topic><topic>Comparative analysis</topic><topic>Gender</topic><topic>Hepatitis B</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Infections</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Mutation</topic><topic>Nucleotide analogs</topic><topic>Patients</topic><topic>Prediction models</topic><topic>Risk factors</topic><topic>Surveillance</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yim, Hyung Joon</creatorcontrib><creatorcontrib>Kang, Seong Hee</creatorcontrib><creatorcontrib>Jung, Young Kul</creatorcontrib><creatorcontrib>Ahn, Sang Hoon</creatorcontrib><creatorcontrib>Kim, Won</creatorcontrib><creatorcontrib>Yang, Jin Mo</creatorcontrib><creatorcontrib>Jang, Jae Young</creatorcontrib><creatorcontrib>Kweon, Yong Oh</creatorcontrib><creatorcontrib>Cho, Yong Kyun</creatorcontrib><creatorcontrib>Kim, Yoon Jun</creatorcontrib><creatorcontrib>Hong, Gun Young</creatorcontrib><creatorcontrib>Kim, Dong Joon</creatorcontrib><creatorcontrib>Sohn, Joo Hyun</creatorcontrib><creatorcontrib>Lee, Jin Woo</creatorcontrib><creatorcontrib>Park, Sung Jae</creatorcontrib><creatorcontrib>Yim, Sun Young</creatorcontrib><creatorcontrib>Park, Jin Kyung</creatorcontrib><creatorcontrib>Um, Soon Ho</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>ProQuest Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yim, Hyung Joon</au><au>Kang, Seong Hee</au><au>Jung, Young Kul</au><au>Ahn, Sang Hoon</au><au>Kim, Won</au><au>Yang, Jin Mo</au><au>Jang, Jae Young</au><au>Kweon, Yong Oh</au><au>Cho, Yong Kyun</au><au>Kim, Yoon Jun</au><au>Hong, Gun Young</au><au>Kim, Dong Joon</au><au>Sohn, Joo Hyun</au><au>Lee, Jin Woo</au><au>Park, Sung Jae</au><au>Yim, Sun Young</au><au>Park, Jin Kyung</au><au>Um, Soon Ho</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-02-22</date><risdate>2024</risdate><volume>16</volume><issue>5</issue><spage>887</spage><pages>887-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>No information is available regarding the influence of besifovir (BSV), a new nucleotide analogue, on the occurrence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study evaluated the reduced risk of HCC in patients undergoing BSV treatment. A total of 188 patients with CHB were treated with BSV for up to 8 years. We prospectively assessed the incidence of HCC compared with the risk from prediction models. During the follow-up, 5 patients developed HCC: 1 of 139 patients with non-cirrhotic CHB, and 4 of 49 patients with liver cirrhosis. We compared the HCC incidence in non-cirrhotic and cirrhotic patients with the predicted number derived from the REACH-B (risk estimation for HCC in CHB) model and GAG-HCC (guide with age, gender, HBV DNA, core promotor mutation, and cirrhosis) model, respectively. The standardized incidence ratio (SIR) was 0.128 (
= 0.039) at 7 years in non-cirrhotic CHB patients, and the SIR was 0.371 (
= 0.047) at 7.5 years in cirrhotic patients, suggesting a significantly decreased HCC incidence in both groups. HCC prediction was available for BSV-treated patients using existing models. In conclusion, BSV decreased the risk of HCC in patients with CHB, and prediction models were applicable. Clinical trial registry website and trial number: ClinicalTrials.gov no: NCT01937806.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38473248</pmid><doi>10.3390/cancers16050887</doi><orcidid>https://orcid.org/0000-0002-5792-1500</orcidid><orcidid>https://orcid.org/0000-0002-2926-1007</orcidid><orcidid>https://orcid.org/0000-0001-9141-7773</orcidid><orcidid>https://orcid.org/0000-0002-8977-4509</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-02, Vol.16 (5), p.887 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10930911 |
| source | PubMed Central Open Access; PubMed (Medline); MDPI - Multidisciplinary Digital Publishing Institute; EZB Electronic Journals Library |
| subjects | Age Antigens Care and treatment Cirrhosis Clinical trials Comparative analysis Gender Hepatitis B Hepatocellular carcinoma Hepatoma Infections Liver Liver cancer Liver cirrhosis Medical research Medicine, Experimental Mutation Nucleotide analogs Patients Prediction models Risk factors Surveillance Ultrasonic imaging |
| title | Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A39%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20Risk%20of%20Hepatocellular%20Carcinoma%20in%20Patients%20with%20Chronic%20Hepatitis%20B%20Receiving%20Long-Term%20Besifovir%20Therapy&rft.jtitle=Cancers&rft.au=Yim,%20Hyung%20Joon&rft.date=2024-02-22&rft.volume=16&rft.issue=5&rft.spage=887&rft.pages=887-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16050887&rft_dat=%3Cgale_pubme%3EA786432137%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2955417904&rft_id=info:pmid/38473248&rft_galeid=A786432137&rfr_iscdi=true |